Company: LHI
Filing Date: 2025-09-29
Form Type: F-1/A
Source: 0001213900-25-092499
Chunk: 120

Company: Living Homeopathy International Ltd.
Filing Date: 2025-09-29
Form: F-1/A
Chunk 120
---
 we intended to hold higher inventories to support promotional activities aimed at stimulating sales
during the downturn; (ii) decrease in tax payable by $110,319 as provisional tax paid was estimated according to net assessable profit
of fiscal year 2023 which was higher than current income tax expense incurred for the fiscal year 2024.

Net cash used in financing activities

Net cash used in financing activities was
$1,299,123 for the year ended March 31, 2025, which primarily resulted from repayment of $232,737, to Hang Seng Bank Limited in accordance
with the property installment loan agreement between Living Homeopathy Limited and Hang Seng Bank Limited dated October 20, 2021 (the
“Hang Seng Mortgage Loans”); (ii) advances of $981,903 to Mr. To, our Chairman and Chief Executive Officer; (iii) increase
in deferred offering costs by $1,007,167 for the IPO related expenses; and offset by the increase of advance from related party by $924,241
by Ms. Hung, one of our shareholders which mainly to finance us for the IPO related expenses.

Net cash used in financing activities was
$574,414 for the year ended March 31, 2024, which primarily resulted from repayment of $171,087, to Hang Seng Bank Limited in accordance
with the property installment loan agreement between Living Homeopathy Limited and Hang Seng Bank Limited dated October 20, 2021 (the
“Hang Seng Mortgage Loans”), repayment of $78,249 to Mr. To, our Chairman and Chief Executive Officer and dividend of $325,078
to Mr. To.

Off-balance Sheet Commitments and Arrangements

As of March 31, 2025 and 2024, we have not
entered into any material off-balance sheet transactions or arrangements.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition, we have not entered into any derivative contracts that are indexed to our own shares and classified as shareholders’ equity, or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity, nor do we have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging